Company Study of Shanghai Kehua Bio-engineering 
  • Jul/2007
  • Hard Copy
  • USD $299
  • Pages:18
  • Single User License
    (PDF Unprintable)       
  • USD $299
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $598
  • Hard Copy + Single User License
  • USD $349
      

After decades' development, the number of enterprises in China diagnostic reagents industry decreased from more than 300 to 80 or so at present. Several large-size enterprises take the majority of market shares. The targeted markets are mainly focused on major diseases such as hepatitis B, hepatitis C, AIDS and syphilitic disease, etc.

Shanghai Kehua Bio-engineering Co., Ltd. started to enter the field of nucleic acid diagnostic reagents in 2003. With the completion of nucleic acid PCR R&D and Production Platform, the Company now has three product categories for hepatitis B, hepatitis C and HIV/AIDS nucleic diagnosis.

The sales revenue of nucleic acid diagnostic reagents only reached RMB 3 million in 2005, while the figure in 2006 rocketed to more than RMB 8 million with a year-on-year growth of 148%.

In 2006, the sales revenue of medical instruments developed by the Company amounted to RMB 17.21 million, up 46.89% from a year earlier. The average growth in recent three years reached as high as about 55%.

Composition of China Diagnostic Reagents Industry



Main Business Revenue Composition of Kehua Bio-Engineering, 2006




1 Business Status Quo and Future Development Strategy
1.1 Diagnostic Reagents
1.2 Future Development

2 Extension of Production Lines
2.1 R&D Investment
2.2 Development of Nucleic Acid Diagnosis
2.3 Business of Medical Instruments

3 Analysis of Corporate Marketing Strategy
3.1 Domestic Market
3.2 Overseas Market
Composition of China Diagnostic Reagents Industry
Main Business Revenue Composition of Kehua Bio-engineering, 2006
Concentration of Main Product Markets in China
Options for Future Development of Kehua Bio-engineering
Staff Composition of Kehua Bio-engineering
Statistics on Product Reserve of Kehua Bio-engineering
Layout of Sales Agencies of Kehua Bio-engineering
Reported Number of Infectious Diseases in China
Sales Patterns of Kehua Bio-engineering
Distribution of AIDS Infected Groups Worldwide, 2006
Analysis of Corporate Advantages
Status Quo of Overseas Development

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统